Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy
Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy
复制标题
DOI：
10.1001/archinternmed.2007.123
复制
发表时间：
2008-01-25
影响因子：
--
通讯作者：
McTiernan, Anne
中科院分区：
文献类型：
--
作者：
Chlebowski, Rowan T.;Anderson, Garnet;McTiernan, Anne
背景：联合激素治疗对乳腺癌检测的影响尚未确定。方法：在妇女健康倡议试验中，我们研究了联合激素治疗对乳腺癌检测的影响，该试验随机选取16 608名绝经后妇女，接受结合马雌激素（0.625 mg/d）加醋酸甲孕酮（2.5 mg/d）或安慰剂治疗。在基线和每年按方案进行乳房x光检查和乳房检查，并根据临床发现进行乳房活检。结合马雌激素和醋酸甲孕酮对乳腺癌检测的影响是在5.6年的干预中通过接受者操作特征分析来评估乳房x光检查结果。结果：与安慰剂相比，马雌激素联合醋酸甲孕酮增加了乳房x线检查异常的累积频率(35.0% vs 23.0%
Background: The effect of combined hormone therapy on breast cancer detection is not established.Methods: We examined the effect of combined hormone therapy on breast cancer detection in the Women's Health Initiative trial, which randomized 16 608 postmenopausal women to receive conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (2.5 mg/d) or placebo. Mammography and breast examinations were performed at baseline and annually per protocol, with breast biopsies based on clinical findings. The effects of conjugated equine estrogens plus medroxyprogesterone acetate on breast cancer detection was determined throughout 5.6 years of intervention using receiver operating characteristic analyses to evaluate mammography results.Results: Conjugated equine estrogens plus medroxyprogesterone acetate increased the cumulative frequency of mammograms with abnormalities vs placebo (35.0% vs 23.0%; P